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Left atriumPrimary cardiac tumors are rare, with an incidence of 0.001–
0.03% in previous autopsy series [1]. The majority of these tumors
are benign myxomas, although a quarter of cases are malignant,
most of these tumors are sarcomas.
In primary cardiac sarcomas, angiosarcoma is the most
common type of sarcoma [2].
Malignant ﬁbrous histiocytoma (MFH) is a type of sarcoma
characterized by a high degree of malignant neoplasm. Its origin is
uncertain and arises in both bone and soft tissue. Sarcomas,
including MFH, comprise the majority of primary cardiac malig-
nant tumors and have a poor prognosis.
The ﬁrst reported case of cardiac MFH was published in 1978 by
Shah et al. [3]. Subsequently, Okamoto et al. [4] reported a case of
MFH that arose from the left atrium (LA) and reviewed an
additional 46 previously reported cases. An analysis of those
47 cases revealed that 29 patients (62%) were females (mean age of
47.1 years) and cardiac MFH was found to occur most frequently in
the LA and to usually attach to the posterior wall; non-cardiac MFH
usually occurs in the limbs, trunk, retroperitoneum, bone, or head.
In this issue of Journal of Cardiology Cases, Kawarabayashi et al.
[5] report a case of primary cardiac MFH (undifferentiated
pleomorphic sarcoma). In their case, transthoracic echocardiogra-
phy revealed cardiac tumors in the LA of a 53-year-old woman
with a 3-month history of worsening dyspnea. The largest tumor
was found to protrude through the mitral valve in diastole. Three of
four tumors were resected during emergency surgery. However,
the residual tumor extension into the left pulmonary vein could
not be removed. Histological ﬁndings of the resected tumors, such
as organized thrombus and myxomatous tissue changes, indicated
that the tumors were benign at that time.
According to the World Health Organization classiﬁcations of
soft tissue tumors released in 2002, the term pleomorphic MFH is
synonymous with undifferentiated pleomorphic sarcoma, whichDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.05.014
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types described: storiform-pleomorphic, giant cell, and inﬂamma-
tory. Myxoﬁbrosarcoma (formerly deﬁned as myxoid variant or
myxoid MFH) remains a distinctive and discrete entity [6]. Accord-
ing to the main morphological characteristics of tumor cells, MFH
can be grouped into four types [7,8].
First is the storiform-pleomorphic type, where the most
prominent morphological features include the fact that the tumor
cells are pleomorphic and have a spoke wheel-like structure,
showing spindle cells arranged in spoke wheel shapes.
A large number of giant cells are stained with a strongly
eosinophilic cytoplasm, and single or multiple irregular nuclei are
present in the multishaped area.
The second type is the giant tumor cell type. The tumor is nodular
and is formed by the ﬁbroblasts, histiocytes, and spread osteoclast-
type giant cells. Some tumors present as malignant, giant tumor cells
with frequent mitotic activity. The tumors are usually hemorrhag-
ing, exhibit necrosis, and sometimes present with bone-like tissue.
The third type is the inﬂammatory type. The most prominent
feature of this type is a large number of foamy yellow tumor cells in
various differentiations mixed with a large number of inﬂamma-
tory cells, particularly neutrophilic granulocytes. Sometimes
poorly differentiated tumor cells have little cytoplasm and large
nuclei, and mitotic activity is usually visible.
The last type is the myxoid type, where the rare tumor cells are
round- or star-shaped and scattered in the loose mucus matrix.
Vacuoles can be seen within the cytoplasm of the tumor cells, which
are similar to the lipoblastoma cells, but special staining shows
acidic mucus in the vacuoles.
Wang et al. [9] reported two cases of cardiac MFH that reviewed
an additional 21 previously reported cases in English in PubMed
since 2002 through 2012 that could be categorized as primary
cardiac MFH when applying the latest released classiﬁcation. The
tumor was often located in the left atrium (11/23), but it could
involve any site, including all chambers, mitral or tricuspid valve,
and pericardium. Just as with cardiac myxomas, cardiac MFH often
manifested cardiorespiratory symptoms in which dyspnea was
most common. Gastrointestinal symptoms, such as abdominal
pain, diarrhea, appetite loss, and nausea, which arose in 7 patients,
appeared more common than that of myxomas [10].
Surgery is the cornerstone of treatment for all soft-tissue
sarcomas. The goal of surgery is to eradicate all of the disease in the
affected area.
In Kawarabayashi’s case, after 3 months emergency surgery, the
patient underwent total resection for a small mass that developed on
her right abdominal wall, which was revealed histologically to be reserved.
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progressively. After undergoing radiation therapy without further
surgery, she died of cerebral bleeding 6 months after cardiac surgery.
Postmortem examination revealed that the tumor in the LA was an
MFH.
Although the case reported here included performing surgical
tumor resections, the tumor featured rapid disease progression,
subsequent relapse, and metastasis. There are few single case
reports of successful chemotherapy and radiotherapy [11].
For MFH, the role of chemotherapy in treatment is not entirely
clear [7]. Several clinical trials incorporating the chemotherapy
drug doxorubicin have shown improved event-free survival
without a major impact on overall survival [12]. Radiation clearly
improves the incidence of local recurrence and has become an
integral part of the treatment for MFH [13,14]. Some factors,
however, contribute to the poor prognosis of MFH, including a lack
of molecular targets for MFH treatment.
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